The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation

Samarth S. Patel, Viviana A. Rodriguez, Mohammad B. Siddiqui, Masoud Faridnia, Fei‐Pi Lin, Anchalia Chandrakumaran, John Laurenzano, Joseph Clinton, Gurukripa N. Kowlgi, Danielle Kirkman, Adam P. Sima, Erika Liptrap, Chandra Bhati, Mohammad Shadab Siddiqui – 25 July 2019 – Cardiovascular disease (CVD) is a major contributor to longterm mortality after liver transplantation (LT) necessitating aggressive modification of CVD risk.

Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase‐A/5‐Hydroxytryptamine/5‐Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis

Konstantina Kyritsi, Lixian Chen, April O’Brien, Heather Francis, Travis W. Hein, Julie Venter, Nan Wu, Ludovica Ceci, Tianhao Zhou, David Zawieja, Anatoliy A. Gashev, Fanyin Meng, Pietro Invernizzi, Luca Fabris, Chaodong Wu, Nicholas J. Skill, Romil Saxena, Suthat Liangpunsakul, Gianfranco Alpini, Shannon S. Glaser – 25 July 2019

Redefining Cirrhotic Cardiomyopathy for the Modern Era

Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee, on behalf of The Cirrhotic Cardiomyopathy Consortium – 25 July 2019 – Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver disease in the absence of prior heart disease. First defined in 2005 during the World Congress of Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical cardiac dysfunction in the absence of overt structural abnormalities.

Reply

Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Guadalupe Garcia‐Tsao, Patrick S. Kamath, Jasmohan S. Bajaj, for the North American Consortium for the Study of the Liver – 25 July 2019

Subscribe to